Evidence map›Paper›PMID 26328262›Full record

ArticleAmerican journal of cancer research2015

Classifying early-onset colorectal cancer according to tumor location: new potential subcategories to explore.

José Perea, Juana M Cano, Daniel Rueda, Juan L García, Lucía Inglada, Irene Osorio, María Arriba, Jessica Pérez, Miriam Gaspar, Tamara Fernández-Miguel and 4 more

Abstract read
In one paragraph

Article in American journal of cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Cancers · 2020
    Article
  6. Early-onset colorectal cancer: initial clues and current views.Nature reviews. Gastroenterology & hepatology · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

José PereaDepartment of Surgery, Hospital Universitario 12 de Octubre Madrid, Spain ; Digestive Cancer Research Group, Hospital 12 de Octubre Research Institute Madrid, Spain.
Juana M CanoDepartment of Medical Oncology, Ciudad Real General Hospital Ciudad Real, Spain.
Daniel RuedaDigestive Cancer Research Group, Hospital 12 de Octubre Research Institute Madrid, Spain ; Molecular Biology Laboratory, Hospital Universitario 12 de Octubre Madrid, Spain.
Juan L GarcíaBiomedical Research Institute of Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC Spain ; Institute of Molecular and Cellular Biology of Cancer (IBMCC), Universidad de Salamanca-CSIC Spain.
Lucía IngladaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO) Madrid, Spain.
Irene OsorioDigestive Cancer Research Group, Hospital 12 de Octubre Research Institute Madrid, Spain.
María ArribaDigestive Cancer Research Group, Hospital 12 de Octubre Research Institute Madrid, Spain.
Jessica PérezBiomedical Research Institute of Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC Spain ; Institute of Molecular and Cellular Biology of Cancer (IBMCC), Universidad de Salamanca-CSIC Spain.
Miriam GasparDigestive Cancer Research Group, Hospital 12 de Octubre Research Institute Madrid, Spain.
Tamara Fernández-MiguelDepartment of Surgery, Hospital Universitario 12 de Octubre Madrid, Spain.
Yolanda RodríguezDepartment of Pathology, Hospital Universitario 12 de Octubre Madrid, Spain.
Javier BenítezHuman Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO) Madrid, Spain ; Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid, Spain.
Rogelio González-SarmientoBiomedical Research Institute of Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC Spain ; Institute of Molecular and Cellular Biology of Cancer (IBMCC), Universidad de Salamanca-CSIC Spain.
Miguel UriosteCenter for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid, Spain ; Familial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO) Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early-onset Colorectal Cancer (ECRC) represents a significant and increasing proportion of Colorectal Cancer (CRC), but it is a heterogeneous entity that probably encompasses specific subclasses. On the premise that the carcinogenetic mechanism and progression of CRC may differ with location, we analyzed molecular and clinical characteristics of ECRC according to tumor location in order to identify more homogeneous subgroups of CRC. Right-sided ECRC is a subset in which most Lynch Syndrome cases are found, with earlier stages at diagnosis and better prognosis. At this location the CpG Island Methylator Phenotype (CIMP) is predominant and Chromosomal Instability (CI) is rare. Left-sided ECRC appears as a transitional or intermediate location, except for CI tumors, that seem to predominate at this location. Finally, rectal ECRC shows Microsatellite Stability, CIMP low-0 and low CI - with recurrent altered chromosomal regions in common with left-sided ECRC-, possibly in relation with Microsatellite And Chromosomal Stable tumors, but with an unexpected familial component and worse prognosis. All this suggest that the molecular basis of ECRC varies with tumor location, which could affect the clinical management of patients.

Indexed as

chromosomal instabilityCpg island methylator phenotypeEarly-onset colorectal cancermicrosatellite instabilitytumor location

Identifiers

PMID26328262
PMCPMC4548343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.